
Dilated Cardiomyopathy - Pipeline Insight, 2024
Description
Dilated Cardiomyopathy - Pipeline Insight, 2024
DelveInsight’s, Dilated Cardiomyopathy - Pipeline Insight, 2024,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Dilated Cardiomyopathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Dilated Cardiomyopathy: Overview
Dilated Cardiomyopathy (DCM) is a disease of the heart muscle characterized by enlargement and dilation of one or both of the ventricles along with impaired contractility defined as left ventricular ejection fraction (LVEF) less than 40%. In most cases DCM is progressive, leading to heart failure and death. Without a transplant, the survival rates are poor.
DCM has many causes and all of them affect the ventricular function to a varying degree. While most patients with DCM have symptoms, a few patients may be asymptomatic because of the compensatory mechanisms. The continued enlargement fo the ventricles leads to a decline in ventricular function, followed by conduction system abnormalities, ventricular arrhythmias, thromboembolism, and heart failure. The earlier these patients are identified and treated, the better the prognosis.
""Dilated Cardiomyopathy - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Dilated Cardiomyopathy pipeline landscape is provided which includes the disease overview and Dilated Cardiomyopathy treatment guidelines. The assessment part of the report embraces, in depth Dilated Cardiomyopathy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Dilated Cardiomyopathy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence R&D Dilated Cardiomyopathy. The therapies under development are focused on novel approaches to treat/improve Dilated Cardiomyopathy.
Danicamtiv: MyoKardia
Danicamtiv (formerly MYK-491) is an oral, small molecule, selective cardiac myosin activator. In the heart, myosin is the motor protein that binds to actin to generate the force and movement of contraction. In patients with dilated cardiomyopathy and systolic heart failure, the left ventricle of the heart is too distended and weak to adequately pump blood to meet the body’s needs. Danicamtiv has been shown to increase the probability for myosin-actin engagement while preserving the detachment of myosin from actin at the end of contraction, thereby improving cardiac contractility while preserving diastolic function and allowing for normal filling.
Ixmyelocel-T: Vericel
Ixmyelocel-T is an investigational autologous expanded multicellular therapy manufactured from the patient's own bone marrow using Vericel's proprietary, highly automated, fully closed cell-processing system. This process selectively expands the population of mesenchymal stromal cells and alternatively activated macrophages, which are responsible for production of anti-inflammatory and pro-angiogenic factors known to be important for repair of damaged tissue. Ixmyelocel-T has been designated as an orphan drug by the US Food and Drug Administration for use in the treatment of DCM.
Further product details are provided in the report……..
Dilated Cardiomyopathy: Therapeutic Assessment
This segment of the report provides insights about the Dilated Cardiomyopathy drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Dilated Cardiomyopathy
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Molecule Type
- Small molecule
- Cell Therapy
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Dilated Cardiomyopathy: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Dilated Cardiomyopathy therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Dilated Cardiomyopathy drugs.
Dilated Cardiomyopathy Report Insights
- Dilated Cardiomyopathy Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Dilated Cardiomyopathy drugs?
- How many Dilated Cardiomyopathy drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Dilated Cardiomyopathy?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Dilated Cardiomyopathy therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Dilated Cardiomyopathy and their status?
- What are the key designations that have been granted to the emerging drugs?
- Renovacor
- Pfizer
- Longeveron
- MyoKardia
- Berlin Cures
- Vericel
- Tenaya Therapeutics
- Cardior Pharmaceuticals
- Help Therapeutics
- REN 001
- Emprumapimod
- Mesenchymal stem cell therapy
- Danicamtiv
- BC 007
- Ixmyelocel-T
- TN 301
- CDR 426D
- hiPSC-CM therapy
Table of Contents
60 Pages
- Introduction
- Executive Summary
- Dilated Cardiomyopathy: Overview
- What is Dilated Cardiomyopathy?
- Types of Dilated Cardiomyopathy
- Causes
- Epidemiology and Risk Factors
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Dilated Cardiomyopathy– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Emprumapimod: Pfizer
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase I/II)
- Comparative Analysis
- Mesenchymal stem cell therapy: Longeveron
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical Stage Products
- Comparative Analysis
- CDR 426D: Cardior Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Dilated Cardiomyopathy Key Companies
- Dilated Cardiomyopathy Key Products
- Dilated Cardiomyopathy- Unmet Needs
- Dilated Cardiomyopathy- Market Drivers and Barriers
- Dilated Cardiomyopathy- Future Perspectives and Conclusion
- Dilated Cardiomyopathy Analyst Views
- Dilated Cardiomyopathy Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.